$PHLT
Performant Healthcare Inc Stock $phlt

$phlt Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000155069521000078 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$31.58M	$28.58M	$40.04M
YoY Change	-21.13%	-21.11%	-8.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$20.09M	$19.31M	$26.16M
YoY Change	-23.22%	-17.92%	-7.82%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.305M	$800.0K	$1.150M
YoY Change	13.48%	-33.33%	-37.5%
% of Gross Profit
Operating Expenses	$28.46M	$28.47M	$36.33M
YoY Change	-21.67%	-17.09%	-6.73%
Operating Profit		$115.0K
YoY Change		-93.92%
Interest Expense	-$5.447M	$2.394M	-$1.400M
YoY Change	289.07%	52.58%	-39.66%
% of Operating Profit		2081.74%
Other Income/Expense, Net	-$25.00K	$579.0K
YoY Change
Pretax Income	-$2.635M	-$1.700M	$2.310M
YoY Change	-214.07%	-615.15%	-149.68%
Income Tax	$1.000K	-$9.000K	-$1.420M
% Of Pretax Income			-61.47%
Net Earnings	-$2.636M	-$1.691M	$3.720M
YoY Change	-170.86%	-185.66%	-196.37%
Net Earnings / Revenue	-8.35%	-5.92%	9.29%
Basic Earnings Per Share		-$0.03
Diluted Earnings Per Share	-$38.03K	-$0.03	$67.93K
COMMON SHARES
Basic Shares Outstanding	69.14M shares	62.13M shares	54.76M shares
Diluted Shares Outstanding		62.13M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.35M	$51.32M	$16.00M
YoY Change	8.42%	226.9%	370.59%
Cash & Equivalents	$17.35M	$51.32M	$16.04M
Short-Term Investments
Other Short-Term Assets	$5.280M	$4.742M	$6.100M
YoY Change	-13.44%	7.77%	24.49%
Inventory
Prepaid Expenses
Receivables	$20.81M	$18.20M	$23.22M
Other Receivables	$3.159M	$3.453M	$4.700M
Total Short-Term Assets	$54.71M	$82.67M	$54.52M
YoY Change	0.34%	68.31%	47.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.71M	$16.28M	$17.50M
YoY Change	-10.22%	-7.75%	-6.78%
Goodwill	$47.40M	$47.40M	$47.40M
YoY Change	0.0%	0.0%	-36.29%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$963.0K	$986.0K	$1.106M
YoY Change	-12.93%	-17.83%	10.6%
Total Long-Term Assets	$67.28M	$68.27M	$71.71M
YoY Change	-6.18%	-5.02%	-29.61%
TOTAL ASSETS
Total Short-Term Assets	$54.71M	$82.67M	$54.52M
Total Long-Term Assets	$67.28M	$68.27M	$71.71M
Total Assets	$122.0M	$150.9M	$126.2M
YoY Change	-3.36%	24.75%	-9.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.124M	$829.0K	$407.0K
YoY Change	176.17%	-39.58%	-83.93%
Accrued Expenses	$3.600M	$2.900M	$3.400M
YoY Change	5.88%	52.63%	54.55%
Deferred Revenue	$600.0K	$0.00	$900.0K
YoY Change	-33.33%	-100.0%	800.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$489.0K	$47.93M	$59.96M
YoY Change	-99.18%	-20.71%	1705.93%
Total Short-Term Liabilities	$17.51M	$61.47M	$77.21M
YoY Change	-77.33%	-18.57%	297.39%
LONG-TERM LIABILITIES
Long-Term Debt	$19.08M	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$1.168M	$3.055M	$3.593M
YoY Change	-67.49%	-22.89%	100.06%
Total Long-Term Liabilities	$20.25M	$3.055M	$3.593M
YoY Change	463.65%	-22.89%	-94.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.51M	$61.47M	$77.21M
Total Long-Term Liabilities	$20.25M	$3.055M	$3.593M
Total Liabilities	$39.56M	$66.55M	$84.25M
YoY Change	-53.04%	-20.14%	-1.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.25M	-$48.61M	-$40.96M
YoY Change	25.12%	8.8%	51.87%
Common Stock	$133.7M	$133.0M	$82.94M
YoY Change	61.17%	61.54%	2.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$82.42M	$84.39M	$41.98M
YoY Change
Total Liabilities & Shareholders Equity	$122.0M	$150.9M	$126.2M
YoY Change	-3.36%	24.75%	-9.11%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$2.636M	-$1.691M	$3.720M
YoY Change	-170.86%	-185.66%	-196.37%
Depreciation, Depletion And Amortization	$1.305M	$800.0K	$1.150M
YoY Change	13.48%	-33.33%	-37.5%
Cash From Operating Activities	-$370.0K	-$178.0K	$2.820M
YoY Change	-113.12%	-107.95%	-238.24%
INVESTING ACTIVITIES
Capital Expenditures	-$721.0K	-$1.091M	-$930.0K
YoY Change	-22.47%	18.59%	22.37%
Acquisitions
YoY Change
Other Investing Activities	-$25.00K	$765.0K
YoY Change
Cash From Investing Activities	-$746.0K	-$326.0K	-$930.0K
YoY Change	-19.78%	-64.57%	22.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-32.86M	41.88M	-870.0K
YoY Change	3677.01%	-4858.86%	16.0%
NET CHANGE
Cash From Operating Activities	-370.0K	-178.0K	2.820M
Cash From Investing Activities	-746.0K	-326.0K	-930.0K
Cash From Financing Activities	-32.86M	41.88M	-870.0K
Net Change In Cash	-33.98M	41.37M	1.020M
YoY Change	-3430.98%	9303.18%	-128.73%
FREE CASH FLOW
Cash From Operating Activities	-$370.0K	-$178.0K	$2.820M
Capital Expenditures	-$721.0K	-$1.091M	-$930.0K
Free Cash Flow	$351.0K	$913.0K	$3.750M
YoY Change	-90.64%	-71.11%	-392.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001550695
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35628
	dei	Entity Registrant Name EntityRegistrantName	PERFORMANT FINANCIAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0484934
	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 North Canyons Parkway
	dei	Entity Address City Or Town EntityAddressCityOrTown	Livermore
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94551
	dei	City Area Code CityAreaCode	(925)
	dei	Local Phone Number LocalPhoneNumber	960-4800
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $.0001 per share
	dei	Trading Symbol TradingSymbol	PFMT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69144336	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51323000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16043000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2253000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	49000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	49000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18203000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23216000	USD
CY2021Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4950000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4466000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2539000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3784000	USD
CY2021Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3453000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	4758000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	82671000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	54520000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16280000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17497000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	689000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	47372000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	47372000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3630000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5043000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	986000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1106000	USD
CY2021Q3	us-gaap	Assets Assets	150939000	USD
CY2020Q4	us-gaap	Assets Assets	126227000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	4500000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	906000	USD
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	47925000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	59957000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5060000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8799000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	829000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	407000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3295000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3841000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	867000	USD
CY2021Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2254000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1014000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2105000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2327000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	61468000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77212000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2020Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2021Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2029000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3442000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3055000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3593000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	66552000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	84247000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69144000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69144000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54764000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54764000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132990000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82933000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48610000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40958000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	84387000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	41980000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	150939000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	126227000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28582000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36228000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92814000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115901000	USD
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19686000	USD
CY2020Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	23522000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	67071000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	74493000	USD
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	8781000	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	10813000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	29896000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	32075000	USD
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	27000000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	28467000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	34335000	USD
	us-gaap	Operating Expenses OperatingExpenses	96967000	USD
	us-gaap	Operating Expenses OperatingExpenses	133568000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	115000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1893000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4153000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17667000	USD
CY2021Q3	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	579000	USD
CY2020Q3	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	0	USD
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	2428000	USD
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	0	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	2394000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	1569000	USD
	us-gaap	Interest Expense InterestExpense	5866000	USD
	us-gaap	Interest Expense InterestExpense	5827000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1700000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	330000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7591000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23476000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1644000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	61000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37653000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41980000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	53625000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-632000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5767000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1691000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	1974000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7652000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17709000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62127000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54684000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57512000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54299000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62127000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54710000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57512000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54299000	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42871000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35033000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-23000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-11000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	540000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	657000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42649000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1691000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	1974000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84387000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-260000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1963000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1997000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5237000	USD
	pfmt	Stock Issued During Period Shares Earn Out Shares Amount StockIssuedDuringPeriodSharesEarnOutSharesAmount	801000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42649000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7652000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17709000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84387000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37653000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7652000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17709000	USD
	pfmt	Impairment Long Lived Asset Held For Use And To Be Disposed Of ImpairmentLongLivedAssetHeldForUseAndToBeDisposedOf	718000	USD
	pfmt	Impairment Long Lived Asset Held For Use And To Be Disposed Of ImpairmentLongLivedAssetHeldForUseAndToBeDisposedOf	88000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	27000000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3883000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4072000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1413000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1886000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1963000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1997000	USD
	pfmt	Interest Expense Debt Issuance Costs And Amortization InterestExpenseDebtIssuanceCostsAndAmortization	2453000	USD
	pfmt	Interest Expense Debt Issuance Costs And Amortization InterestExpenseDebtIssuanceCostsAndAmortization	1145000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-162000	USD
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	2428000	USD
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4270000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4756000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	484000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	1523000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1245000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-298000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1305000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	3555000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-120000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3739000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1081000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	422000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1160000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1363000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1664000	USD
	pfmt	Increase Decrease In Estimated Liability For Appeals IncreaseDecreaseInEstimatedLiabilityForAppeals	1240000	USD
	pfmt	Increase Decrease In Estimated Liability For Appeals IncreaseDecreaseInEstimatedLiabilityForAppeals	15000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1635000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1907000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-445000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2168000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1286000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17992000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2695000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2862000	USD
	pfmt	Proceeds From Sale Of Recovery Contracts ProceedsFromSaleOfRecoveryContracts	3171000	USD
	pfmt	Proceeds From Sale Of Recovery Contracts ProceedsFromSaleOfRecoveryContracts	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	476000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2862000	USD
	pfmt	Repayments Of Long Term Notes Payable RepaymentsOfLongTermNotesPayable	8438000	USD
	pfmt	Repayments Of Long Term Notes Payable RepaymentsOfLongTermNotesPayable	2588000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	633000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	260000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42648000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33468000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2848000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	35230000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12282000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18296000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4995000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53526000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17277000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51323000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15655000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1622000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53526000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17277000	USD
	pfmt	Recognition Of Earn Out Shares Issued Non Cash Financing Activity RecognitionOfEarnOutSharesIssuedNonCashFinancingActivity	801000	USD
	pfmt	Recognition Of Earn Out Shares Issued Non Cash Financing Activity RecognitionOfEarnOutSharesIssuedNonCashFinancingActivity	0	USD
	pfmt	Recognitionof Warrant Issued Non Cash Financing Activity RecognitionofWarrantIssuedNonCashFinancingActivity	5237000	USD
	pfmt	Recognitionof Warrant Issued Non Cash Financing Activity RecognitionofWarrantIssuedNonCashFinancingActivity	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-683000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-2280000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3413000	USD
	us-gaap	Interest Paid Net InterestPaidNet	4616000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Revenue Recognition Interest RevenueRecognitionInterest	Revenues, Accounts Receivable, Contract Assets, Contract Liabilities, Estimated Liability for Appeals, Disputes and Refunds <div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives its revenues primarily from providing audit, recovery, and analytics services. Revenues are recognized upon completion of these services for its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts generally contain a single performance obligation, delivered over time as a series of services that are substantially the same and have the same pattern of transfer to the client, as the promise to transfer the individual services is not separately identifiable from other promises in the contracts and, therefore, not distinct.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts are composed primarily of variable consideration. Fees earned under the Company’s audit and recovery service contracts consist primarily of contingency fees based on a specified percentage of the amount the Company enables its clients to recover. The contingency fee percentage for a particular recovery depends on the type of recovery or claim facilitated. In certain contracts, the Company can earn additional performance-based bonuses determined based on its performance relative to the client’s other contractors providing similar services.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally either applies the as-invoiced practical expedient where its right to consideration corresponds directly to its right to invoice its clients, or the variable consideration allocation exception where the variable consideration is attributable to one or more, but not all, of the services promised in a series of distinct services that form part of a single performance obligation. As such, the Company has elected the optional exemptions related to the as-invoiced practical expedient and the variable consideration allocation exception, whereby the disclosure of the amount of transaction price allocated to the remaining performance obligations is not required. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates variable consideration only if it can reasonably measure the progress toward complete satisfaction of the performance obligation using an output method based on reliable information, and recognizes such revenue over the performance period only if it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Any change made to the measure of progress toward complete satisfaction of the Company’s performance obligation is recorded as a change in estimate. The Company exercises judgment to estimate the amount of constraint on variable consideration based on the facts and circumstances of the relevant contract operations and the availability and reliability of data. Although the Company believes the estimates made are reasonable and appropriate, different assumptions and estimates could materially impact the amount of variable consideration.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts that contain a refund right, these amounts are considered variable consideration and the Company estimates its refund exposure and recognizes revenue net of such estimate.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain contracts, consideration can include periodic performance-based bonuses which can be awarded based on the Company’s performance under the specific contract. These performance-based bonuses are considered variable and may be constrained by the Company until there is not a risk of a significant reversal.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied the as-invoiced practical expedient or the variable consideration allocation exception to contracts with performance obligations that have an average remaining duration of less than a year.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For healthcare claims-based audit contracts, the Company may recognize revenue upon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivering the results of claims audits, when sufficient reliable information is available to the Company for estimating the variable consideration earned based on an output metric that reasonably measures the Company's satisfaction of its performance obligation.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For eligibility-based or COB contracts, the Company recognizes revenue when insurance companies or other responsible parties have remitted payments to its clients.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain recovery contracts, revenue is recognized when the clients collect on amounts owed to them as a result of the Company’s services. For student loan recovery services, loan rehabilitation revenue is recognized when the rehabilitated loans are funded by clients. Bonuses are recognized upon receipt of official notification of bonus awards from customers.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For customer care / outsourced services, the Company recognizes revenues based on the volume of processed transactions or the quantity of labor hours provided.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company determines the allowance for doubtful accounts by specific identification. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is consider remote. The allowance for doubtful accounts was $49 thousand at September 30, 2021 and December 31, 2020. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers have the right to appeal claims audit findings and may pursue additional appeals if the initial appeal is found in favor of healthcare clients. For eligibility or COB contracts, insurance companies or other responsible parties may dispute the Company’s findings regarding our clients not being the primary payer of healthcare claims. Total estimated liability for appeals, disputes, and refunds was $2.3 million as of September 30, 2021 and $1.0 million as of December 31, 2020. This represents the Company’s best estimate of the amount probable of being refunded to the Company’s healthcare clients. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that it does not have any material costs related to obtaining or fulfilling a contract that are recoverable and as such, these contract costs are generally expensed as incurred.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets was approximately $5.0 million and $4.5 million as of September 30, 2021 and December 31, 2020, respectively. Contract assets relate to the Company’s rights to consideration for services completed, but not invoiced at the reporting date, and receipt of payment is conditional upon factors other than the passage of time. Contract assets primarily consist of commissions the Company estimates it has earned from completed claims audit findings submitted to healthcare clients. Generally, the Company’s right to payment occurs when contract assets are recorded to accounts receivable when the rights become unconditional, which is generally when healthcare providers or payers have paid our clients. There was no impairment loss related to contract assets for the nine months ended September 30, 2021.</span></div>Contract liabilities was $0.0 million and $0.9 million as of September 30, 2021 and December 31, 2020, respectively, and are included in deferred revenue on the consolidated balance sheets. The Company’s contract liabilities mainly relate to an advance recovery commission payment received from a client.
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28582000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36228000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92814000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115901000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	49000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	49000	USD
CY2021Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2300000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1000000	USD
CY2021Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	5000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	4500000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2300000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	73078000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	78317000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16280000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17497000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	800000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	1200000	USD
	us-gaap	Depreciation Depreciation	3200000	USD
	us-gaap	Depreciation Depreciation	3900000	USD
CY2021Q2	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	6000000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	900000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2500000	USD
CY2021Q3	pfmt	Prepaid Expenseand Other Assets Prepaid Software Licenses And Maintenance Agreements PrepaidExpenseandOtherAssetsPrepaidSoftwareLicensesAndMaintenanceAgreements	1800000	USD
CY2021Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	700000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3800000	USD
CY2020Q4	pfmt	Prepaid Expenseand Other Assets Prepaid Software Licenses And Maintenance Agreements PrepaidExpenseandOtherAssetsPrepaidSoftwareLicensesAndMaintenanceAgreements	1800000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1400000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	600000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	47400000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	47400000	USD
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	34200000	USD
CY2021Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	34200000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	600000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2900000	USD
CY2021Q3	pfmt	Workers Compensation Liability Incurred WorkersCompensationLiabilityIncurred	400000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3400000	USD
CY2020Q4	pfmt	Workers Compensation Liability Incurred WorkersCompensationLiabilityIncurred	200000	USD
CY2020Q4	pfmt	Premium Insurance Financing Payables PremiumInsuranceFinancingPayables	200000	USD
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	2400000	USD
	pfmt	Proceeds From Sale Of Recovery Contracts ProceedsFromSaleOfRecoveryContracts	3200000	USD
CY2021Q3	us-gaap	Severance Costs1 SeveranceCosts1	400000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	1900000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	89358000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95814000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4500000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	47925000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	47925000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	800000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1800000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067
	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	660000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2009000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	873000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	594000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	398000	USD
CY2021Q3	pfmt	Lessee Operating Lease Liabilitytobe Paid Dueafter Year Four LesseeOperatingLeaseLiabilitytobePaidDueafterYearFour	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4534000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	400000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4134000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	700000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62127000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54684000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57512000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54299000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	26000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62127000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54710000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57512000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54299000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11027	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12369	shares

Files In Submission

Name	View Source	Status
0001550695-21-000078-index-headers.html	Edgar Link	pending
0001550695-21-000078-index.html	Edgar Link	pending
0001550695-21-000078.txt	Edgar Link	pending
0001550695-21-000078-xbrl.zip	Edgar Link	pending
ex093021311cert.htm	Edgar Link	pending
ex093021312cert.htm	Edgar Link	pending
ex093021321cert.htm	Edgar Link	pending
ex093021322cert.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pfmt-20210930.htm	Edgar Link	pending
pfmt-20210930.xsd	Edgar Link	pending
pfmt-20210930_cal.xml	Edgar Link	unprocessable
pfmt-20210930_def.xml	Edgar Link	unprocessable
pfmt-20210930_htm.xml	Edgar Link	completed
pfmt-20210930_lab.xml	Edgar Link	unprocessable
pfmt-20210930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHLT
Performant Healthcare Inc Stock $phlt

2021 Q4 Form 10-Q Financial Statement

#000155069521000078 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHLT Performant Healthcare Inc Stock $phlt

2021 Q4 Form 10-Q Financial Statement

#000155069521000078 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHLT
Performant Healthcare Inc Stock $phlt